Invitae

Affordable genetic testing for healthcare access

San Francisco, California, United States

Visit Website View Jobs

About Invitae

Invitae specializes in genetic testing, aiming to incorporate genetic information into standard medical practices. The company offers a range of tests for hereditary conditions, reproductive health, and proactive health assessments, making these services affordable and accessible to a wide audience. Invitae's testing process is streamlined for both patients and clinicians, allowing for easy ordering, sample pickups, and result tracking. Unlike many competitors, Invitae focuses on reducing costs and simplifying access to genetic testing, including offering sponsored programs for no-cost testing in certain cases. The goal is to empower patients and healthcare providers with valuable genetic insights that can enhance health outcomes.

San Francisco, CaliforniaHeadquarters
2010Year Founded
$190.2MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Competitive salary
Health, dental, & vision
Generous vacation days
Family leave
Flexible working hours
Work from home

Risks

Labcorp acquisition may disrupt operations and affect customer satisfaction.
Financial instability from bankruptcy poses risks to ongoing operations.
Uncertainty about San Francisco labs could impact research and development.

Differentiation

Invitae offers comprehensive genetic tests with faster turnaround and lower costs.
The company integrates AI and machine learning to enhance diagnostic accuracy.
Invitae's platform simplifies test ordering, sample pickup, and result tracking.

Upsides

Growing demand for genetic testing boosts Invitae's market potential.
AI integration improves diagnostic speed and accuracy, enhancing service value.
Telemedicine expansion allows Invitae to reach a broader audience.

Funding

Total raised$190.17 M
Latest valuation$239.00 M
StageIPO
ACQUISITION
7/31/2024
$239
$239.00 M
POST IPO CONVERTIBLE
3/31/2021
$1.1 K
$7.70 B
POST IPO EQUITY
3/31/2020
$184
POST IPO DEBT
8/31/2019
$300
POST IPO SECONDARY
10/31/2016
$44
IPO
1/31/2015
$112
$516.00 M
SERIES F
9/30/2014
$120
$600.00 M
SERIES E
11/30/2013
$40
$200.00 M
SERIES A
10/31/2012
$30
$147.80 M
EARLY VC
2/28/2011
$2
$11.50 M